#United States #San Francisco #Cholesterol Guidelines #Andrew Ambrosy #LDL Levels

Introduction

In a significant update announced by the American Heart Association and the American College of Cardiology, cardiologist Andrew P. Ambrosy, MD, MPH, shared the newly revised cholesterol treatment guidelines, the first major changes since 2018. This shift emphasizes the need for earlier cholesterol checks, initiating treatment sooner, and setting lower target levels for low-density lipoprotein (LDL) cholesterol.

Key Changes in Screenings

Historically, cholesterol screenings typically began in adulthood. However, recent findings indicate that children can also have elevated cholesterol, particularly those with a family history of hypercholesterolemia—an inherited condition that affects approximately 1 in 250 individuals. The updated guidelines suggest a first cholesterol test be conducted during grade school, around the ages of 9 to 11. The rationale is to identify familial high cholesterol early, thereby allowing for fast-tracked treatment and averting potential health issues in the future.

The Importance of Targeted Treatment

With cardiovascular disease being the leading cause of death in the U.S., the stakes for early detection are high. According to statistics, it accounts for about 700,000 preventable deaths each year. Ambrosy remarks, "Cholesterol is a lifetime exposure, not a midlife problem," stressing that understanding one's cholesterol numbers earlier can significantly affect long-term heart health.

Base-Level Adjustments

One notable shift in the new guidelines involves how treatment eligibility is determined. Instead of looking at a 10-year risk only, clinicians will now evaluate a 30-year risk, capturing individuals who might have been previously categorized as low-risk but are actually at considerable risk due to poor lipid profiles. A 40-year-old with unhealthy cholesterol levels is no longer deemed safe but is flagged for necessary intervention.

Goal-Oriented LDL Levels

For the first time in years, the guidelines reinstate specific LDL targets that doctors should aim for. For at-risk patients—those who've experienced a heart attack or stroke, or have additional risk factors like diabetes—the target LDL is set at 55 mg/dL or lower, marking a reduction from the previous target of 70 mg/dL. For those not at risk, the target is set at 100 mg/dL or below. Ambrosy explains, "A target provides both the patient and the doctor with something concrete to work towards, allowing for measurable assessment of the treatment effectiveness."

Evaluating Lp(a) Levels

Adults visiting their healthcare providers for cholesterol checks should also consider getting a lipoprotein(a), or Lp(a), biomarker test. This test, often neglected in the past, is critical as high Lp(a) levels can signify increased risk for inflammation leading to heart attacks. Importantly, while LDL levels can be modified through diet, exercise, or medication, Lp(a) is a fixed characteristic determined by genetics. Understanding one’s Lp(a) level will guide how aggressively to manage overall health and treatment plans.

Long-term Risk Assessment

The new guidelines pivot towards a preventive approach to heart health. With the introduction of the Predicting Risk of Cardiovascular EVENTs (PREVENT) calculator, healthcare providers will evaluate both 10 and 30-year risk estimates based on patient screenings and health history. This comprehensive assessment includes considerations of kidney and metabolic health, which play significant roles in heart disease risk.

Conclusion

Even with these updates, Ambrosy encourages maintaining core health practices like a balanced diet, regular exercise, and quitting smoking. He reinforces the idea that no medication can replace the benefits of such lifestyle changes. Ambrosy urges everyone to remain proactive: "Know your LDL and Lp(a) levels, and appreciate your long-term cardiovascular risk. This is a valuable discussion to have during routine check-ups, regardless of age."

About Dr. Andrew P. Ambrosy

Dr. Andrew P. Ambrosy is a physician-scientist at Kaiser Permanente Northern California Division of Research, specializing in cardiovascular, renal, and metabolic diseases. His work revolves around producing real-world evidence through health service research and clinical trials. He advocates for improvements in heart health based on extensive research to combat preventable cardiovascular diseases effectively.